fda

Attruby (acoramidis), a Near Complete TTR Stabilizer (90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

- Attruby is the first and only approved product with aspecifying near-complete stabilization of TTR. Attruby has been…

4 weeks ago

Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs

Heart disease in dogs is almost as common as it is in humans, affecting approximately 10 percent of dogs in…

4 weeks ago

Attruby (acoramidis), a Near Complete TTR Stabilizer (90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

- Attruby is the first and only approved product with aspecifying near-complete stabilization of TTR. Attruby has been…

4 weeks ago

Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs

Heart disease in dogs is almost as common as it is in humans, affecting approximately 10 percent of dogs in…

4 weeks ago

Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs

Heart disease in dogs is almost as common as it is in humans, affecting approximately 10 percent of dogs in…

4 weeks ago

Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs

Heart disease in dogs is almost as common as it is in humans, affecting approximately 10 percent of dogs in…

1 month ago

Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs

Heart disease in dogs is almost as common as it is in humans, affecting approximately 10 percent of dogs in…

1 month ago

Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA

SAN FRANCISCO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Siren Biotechnology, pioneer of AAV immuno-gene therapy for cancer, today revealed its…

1 month ago

AlveoGene Receives Rare Pediatric Disease Designation (RPDD)from FDA for AVG-002, its Novel, Inhaled Gene Therapy forLethal Neonatal Surfactant Protein B (SP-B) Deficiency

Inherited SP-B deficiency is an ultra-rare monogenic cause of fatal respiratory distress syndrome in newborn infantsClinical estimates for SP-B deficiency…

1 month ago

Revolutionizing Heart Health: Frontier X Plus Gains FDA Clearance

NEW YORK, Nov. 13, 2024 /PRNewswire/ -- Fourth Frontier, a medical technology company based out of New York and Bangalore,…

1 month ago
Show more Posts
Show previous Posts